adobe.stock.com - CathyA month after China publicly revealed its bioeconomy priorities under its 15th Five Year Plan, the European Commission released an updated EU Bioeconomy Strategy — and the contrast could hardly be sharper. While China bets on a bold mix of AI, bioengineering and synthetic biology to replace fossil based industrial products with recombinant and cell free systems, the EU remains anchored in a more traditional vision focused on the valorisation of agricultural output and industrial waste. By contrast, the UK has taken a more modern approach, heavily investing in engineering biology — the use of reprogrammed microorganisms to produce industrial goods — as a key pillar of its biotech and bioeconomy strategy.
Tag Archive for: China
U.S. Department of CommerceAfter the surprising announcement of a 100% tariff on all prescription drugs imported into the United States, the US government appears to be backtracking. Within a few days, its trade policy stance towards the pharmaceutical industry has shifted fundamentally.
AstraZenecaAstraZeneca announces a US$50 billion investment in the USA amid pharma’s transatlantic drift. Virgina is set to become the multi-billion-dollar drug manufacturing hub.
adobe stock photo - JR-50Cultivated meat is expected to reach price parity with conventional meat sooner than previously forecast, according to a new analysis by technology foresight specialist GetFocus.
Jeremy Levin, Ovid TherapeuticsOn May 12, 2025, President Donald Trump signed an executive order aiming to drastically reduce U.S. prescription drug prices by aligning them with the lowest prices paid in other developed nations—a policy known as the “Most Favored Nation” (MFN) approach. While the initiative seeks to alleviate the financial burden on American patients, it has sparked intense debate over its potential ramifications on global pharmaceutical trade, investment patterns, and the United States’ leadership in biomedical innovation.
Ovid Therapeutics - Jeremy LevinBy Jeremy Levin, D.Phil, MB BChir
Jeremy Levin, Ovid TherapeuticsThe U.S. House of Representatives recently passed the BIOSECURE Act, prohibiting U.S. biopharma companies from working with Chinese contractors due to national security concerns, including data leaks and intellectual property theft. The Act is expected to pass the Senate.
The BIOSECURE Act of the United States could affect more than 120 US biopharmaceutical drugs partnered with Chinese companies ‘of concern’, as named in the bill. Of these, approximately half are in clinical trials (phases I to III) and a third are in early preclinical and discovery stages, according to GlobalData, the analytics company.